Gene-Editing Drug Slashes Bad Cholesterol by 62% in Small Trial

A gene-editing drug has shown significant promise in reducing bad cholesterol levels in a small trial involving 35 participants. The drug's effectiveness was observed over several months, indicating potential for long-term cardiovascular health benefits. This development could lead to new treatment options for high cholesterol.